Table 1.
Guidelines on testing and treatment of uncomplicated chlamydia (CT) in asymptomatic women and MSM
| Testing and treatment^ | Urogenital CT | Pharyngeal CT | Rectal CT |
|---|---|---|---|
| Europe (6), UK (7), Australia (9), US (8) | Routine testing (or when a change of sex partner occurs) in people < 25 or 30 years of age and in key populations; implementation in countries varies (e.g., age-based, or by behavioural risk, specific settings/venues) in women and MSM | No testing or selective testing based on reports of oral sex or symptoms in women at STI clinics. Several countries recommend routine testing in MSM | No testing or selective testing based on reports of anal sex or symptoms in women at STI clinics. Most countries recommend routine testing in MSM |
| Treatment* | |||
| Europe (‘15)# | Azithromycin | Azithromycin | Doxycycline |
| UK (‘18) | Doxycycline | Doxycycline | Doxycycline |
| Australia# | Doxycycline or Azithromycin | Doxycycline or Azithromycin | Doxycycline |
| USA (2021) | Doxycycline | Doxycycline | Doxycycline |
^Concerns opportunistic/targeted testing. In addition, in some countries, young people could/can enter community-based testing programs
*Recommended first-line treatment shown
#In the progress of revising guidance